Growth Metrics

Gilead Sciences (GILD) Free Cash Flow Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 27.23%
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 41.47%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -15.10%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -3.92%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 106.58%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 27.06%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 14.07%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 210.20%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -34.49%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 14.07%
Dec 31, 2025 9.38%
Sep 30, 2025 13.54%
Jun 30, 2025 -24.29%
Mar 31, 2025 1.24%
Dec 31, 2024 -2.48%
Sep 30, 2024 10.21%
Jun 30, 2024 -18.37%
Mar 31, 2024 -4.73%
Dec 31, 2023 4.04%
Sep 30, 2023 -7.97%
Jun 30, 2023 -3.18%
Mar 31, 2023 8.93%
Dec 31, 2022 0.13%
Sep 30, 2022 3.44%
Jun 30, 2022 -8.38%
Mar 31, 2022 5.93%
Dec 31, 2021 13.29%
Sep 30, 2021 15.05%
Jun 30, 2021 19.86%
Mar 31, 2021 5.91%
Dec 31, 2020 -11.85%
Sep 30, 2020 -6.52%
Jun 30, 2020 -10.70%
Mar 31, 2020 -23.33%
Dec 31, 2019 -10.98%
Sep 30, 2019 -16.47%
Jun 30, 2019 -23.30%
Mar 31, 2019 -30.27%
Dec 31, 2018 -28.05%
Sep 30, 2018 -18.73%
Jun 30, 2018 -38.51%
Mar 31, 2018 -28.27%
Dec 31, 2017 -3.90%
Sep 30, 2017 -13.10%
Jun 30, 2017 -5.98%
Mar 31, 2017 25.98%
Dec 31, 2016 72.36%
Sep 30, 2016 80.28%
Jun 30, 2016 73.99%
Mar 31, 2016 84.13%
Dec 31, 2015 134.56%
Sep 30, 2015 77.72%
Jun 30, 2015 63.59%
Mar 31, 2015 134.99%
Dec 31, 2014 44.19%
Sep 30, 2014 67.43%
Jun 30, 2014 64.68%
Mar 31, 2014 20.34%
Dec 31, 2013 -2.11%
Sep 30, 2013 -0.58%
Jun 30, 2013 9.94%
Mar 31, 2013 -1.32%
Dec 31, 2012 -22.26%
Sep 30, 2012 -6.95%
Jun 30, 2012 27.68%
Mar 31, 2012 -3.43%